TY - JOUR T1 - The role of nonspecific inflammation factors – SA-A and pentraxin-3 in patients with respiratory sarcoidosis in different age groups JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA701 VL - 58 IS - suppl 65 SP - PA701 AU - Natalya Demyanenko AU - Averbakh Mihail AU - Natalya Makaryants AU - Elena Vladimirova AU - Anna Egorova AU - Aminat Akhmedova Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA701.abstract N2 - Objective: To study the level of nonspecific inflammation factors – SA-A and pentraxin-3 in patients with respiratory sarcoidosis in different age groups. Materials and methods: The survey included 74 patients with newly diagnosed and recurrent sarcoidosis aged under and over 40. The parameters of SA-A and pentraxin -3 in blood plasma were studied. The upper normal level for SA-A was set as 10 μg / ml, for pentraxin-3 - 2 ng / ml (according to the standard).Results: The level of pentraxin -3 in the age group under 40 with newly diagnosed sarcoidosis was 1.05 ± 0.09 ng / ml, in the age group over 40 the level was 1.0 ± 0 (within normal limits). In the group of patients with recurrent sarcoidosis its level was also within normal limits. When examining the SA-A level in the age group over 40 with newly diagnosed sarcoidosis, it was 15.9 ± 0.7 ng / ml, which was initially significantly higher than in the age group under 40. In the group with recurrent course of the disease the SA-A level was higher than normal in both age groups (13.7 ± 1.6 and 14.2 ± 1.7 ng / ml, respectively).Conclusion: In the study of blood serum, the level of pentraxin-3 remained unchanged regardless of age and course of sarcoidosis. Whereas the SA-A level was initially elevated in the group with a relapsing course of the disease. In the age group under 40 with newly diagnosed sarcoidosis its level was significantly higher than in the age group over 40.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA701.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -